Rigel Pharmaceuticals Stock Buy Hold or Sell Recommendation
| RIGL Stock | USD 22.33 0.83 3.86% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Rigel Pharmaceuticals is 'Strong Sell'. The recommendation algorithm takes into account all of Rigel Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Rigel Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide. Note, we conduct extensive research on individual companies such as Rigel and provide practical buy, sell, or hold advice based on investors' constraints. Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Rigel |
Execute Rigel Pharmaceuticals Buy or Sell Advice
The Rigel recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Rigel Pharmaceuticals. Macroaxis does not own or have any residual interests in Rigel Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Rigel Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Rigel Pharmaceuticals Trading Alerts and Improvement Suggestions
| Rigel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Rigel Pharmaceuticals has high historical volatility and very poor performance | |
| Rigel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 116.88 M. Net Loss for the year was (25.09 M) with profit before overhead, payroll, taxes, and interest of 119.79 M. | |
| Rigel Pharmaceuticals currently holds about 81.64 M in cash with (5.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 2036 shares by Schorno Dean L of Rigel Pharmaceuticals at 20.921 subject to Rule 16b-3 |
Rigel Pharmaceuticals Returns Distribution Density
The distribution of Rigel Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Rigel Pharmaceuticals' future price movements. The chart of the probability distribution of Rigel Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Rigel Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Rigel Pharmaceuticals returns is essential to provide solid investment advice for Rigel Pharmaceuticals.
| Mean Return | -0.0037 | Value At Risk | -7.48 | Potential Upside | 7.91 | Standard Deviation | 4.53 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Rigel Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Rigel Stock Institutional Investors
| Shares | Hillsdale Investment Management Inc. | 2024-12-31 | 170.1 K | Goldman Sachs Group Inc | 2024-12-31 | 166.9 K | Northern Trust Corp | 2024-12-31 | 145.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 139.1 K | Norges Bank | 2024-12-31 | 129.5 K | Qube Research & Technologies | 2024-12-31 | 118 K | Nuveen Asset Management, Llc | 2024-09-30 | 115.2 K | Ing Investment Management Llc | 2024-12-31 | 108.6 K | Kennedy Capital Management Inc | 2024-09-30 | 94.5 K | Blackrock Inc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M |
Rigel Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 7.9M | (11.5M) | 5.6M | 8.3M | 7.5M | 7.9M | |
| Free Cash Flow | (53.4M) | 5.3M | (74.2M) | (20.7M) | (18.7M) | (19.6M) | |
| Depreciation | 706K | 1.2M | 998K | 1.2M | 1.1M | 1.7M | |
| Other Non Cash Items | (122K) | 3.1M | 481K | (213K) | (191.7K) | (201.3K) | |
| Capital Expenditures | 1.3M | 627K | 450K | 15M | 17.3M | 18.1M | |
| Net Income | (29.7M) | (17.9M) | (58.6M) | (25.1M) | (22.6M) | (23.7M) | |
| End Period Cash Flow | 30.4M | 18.9M | 24.5M | 32.8M | 37.7M | 32.8M | |
| Change To Inventory | (126K) | (4.9M) | (2.4M) | 1.2M | 1.3M | 1.4M | |
| Investments | 48.7M | (79.4M) | 72.3M | 21.2M | 24.4M | 13.4M | |
| Change To Netincome | 9.1M | 7.3M | 12.9M | 13.1M | 11.8M | 7.6M | |
| Change Receivables | (6.0M) | (5.9M) | 501K | (24.8M) | (22.4M) | (21.2M) |
Rigel Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Rigel Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Rigel Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Rigel stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0 | |
β | Beta against Dow Jones | 2.61 | |
σ | Overall volatility | 4.69 | |
Ir | Information ratio | -0.0016 |
Rigel Pharmaceuticals Volatility Alert
Rigel Pharmaceuticals exhibits very low volatility with skewness of 0.48 and kurtosis of 2.04. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Rigel Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Rigel Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Rigel Pharmaceuticals Fundamentals Vs Peers
Comparing Rigel Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rigel Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Rigel Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rigel Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Rigel Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rigel Pharmaceuticals to competition |
| Fundamentals | Rigel Pharmaceuticals | Peer Average |
| Return On Equity | -6.99 | -0.31 |
| Return On Asset | 0.0461 | -0.14 |
| Profit Margin | 0.02 % | (1.27) % |
| Operating Margin | 0.25 % | (5.51) % |
| Current Valuation | 377.66 M | 16.62 B |
| Shares Outstanding | 17.61 M | 571.82 M |
| Shares Owned By Insiders | 2.80 % | 10.09 % |
| Shares Owned By Institutions | 69.10 % | 39.21 % |
| Number Of Shares Shorted | 560.73 K | 4.71 M |
| Price To Earning | (5.63) X | 28.72 X |
| Price To Book | 31.64 X | 9.51 X |
| Price To Sales | 2.50 X | 11.42 X |
| Revenue | 116.88 M | 9.43 B |
| Gross Profit | 119.79 M | 27.38 B |
| EBITDA | (16.98 M) | 3.9 B |
| Net Income | (25.09 M) | 570.98 M |
| Cash And Equivalents | 81.64 M | 2.7 B |
| Cash Per Share | 0.47 X | 5.01 X |
| Total Debt | 60.58 M | 5.32 B |
| Current Ratio | 2.34 X | 2.16 X |
| Book Value Per Share | (0.83) X | 1.93 K |
| Cash Flow From Operations | (5.74 M) | 971.22 M |
| Short Ratio | 1.97 X | 4.00 X |
| Earnings Per Share | 0.28 X | 3.12 X |
| Price To Earnings To Growth | (0.10) X | 4.89 X |
| Target Price | 32.0 | |
| Number Of Employees | 147 | 18.84 K |
| Beta | 1.34 | -0.15 |
| Market Capitalization | 393.34 M | 19.03 B |
| Total Asset | 117.22 M | 29.47 B |
| Retained Earnings | (1.41 B) | 9.33 B |
| Working Capital | 46 M | 1.48 B |
| Current Asset | 129.02 M | 9.34 B |
Note: Disposition of 2036 shares by Schorno Dean L of Rigel Pharmaceuticals at 20.921 subject to Rule 16b-3 [view details]
Rigel Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Rigel . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Rigel Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Rigel Pharmaceuticals? Buying financial instruments such as Rigel Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Rigel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Rigel Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.28 | Revenue Per Share | Quarterly Revenue Growth 0.966 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.